- Industry
- Health and life sciences
- Elad’s role
- Advisor
The business need
A new diagnostic or biotech product is judged against the clinical gold standard it aims to displace, for example a non-invasive biomarker test against a biopsy. That comparison shapes the go-to-market strategy, the target product profile and the clinical credibility of the product.
What Elad did
- Advised biotech and diagnostic ventures on positioning against the clinical gold standard, for example non-invasive biomarkers against biopsy.
- Helped identify the right comparator or gold standard each technology needed to beat.
- Sharpened the ventures' go-to-market strategy and target product profiles.
- Sharpened the case for the products' clinical credibility.
Decisions this experience speaks to
- We're comparing our technology to an existing clinical gold standard - is that even the right comparison, and how do we position against it?
- We have a scientifically impressive platform, but we're not sure it's solving the problem the market actually needs solved - how do we find out?
- We need to translate complex biological or clinical data into a story that investors, pharma partners, or non-specialist stakeholders will actually understand and back?
Related services and use cases
Sources
This case describes Elad Katz’s own work before Grand Rounds, as Elad’s profile and the public sources above describe it. It is not a Grand Rounds engagement and not a promise of the same result for another company.